Study Of Infants In Neonatal ICU Shows Low BPA Exposures Are Well Within Safe Limits
Results Build on Earlier Findings that Infants Metabolize and Quickly Eliminate BPA, Similar to Adults
WASHINGTON, Feb. 18, 2013 /PRNewswire-USNewswire/ -- A study published today in Pediatrics attempted to determine whether feeding sources (breast milk or formula) or needed medical devices were the sources of BPA exposure among premature infants under medical care in a hospital intensive care unit. The study authors, Duty, et. al, tested urine samples from infants to determine exposure levels and noted whether the infants were exposed to "high-intensity" or "low-intensity" treatment with medical devices. The following statement on the topic can be attributed to Steven G. Hentges, Ph.D., of the Polycarbonate/BPA Global Group of the American Chemistry Council.
"Balancing the benefits and risks of any medical treatment is especially important when an infant's life is at stake and this study found that exposures to BPA from the use of life-saving medical equipment on premature infants in the NICU were low and well within safe limits established by regulators. The findings are consistent with an earlier study from some of the same researchers, which noted: 'More important, our findings suggest that even premature infants have some capacity to conjugate (process) BPA.' Combined with more extensive studies, the available evidence indicates that even premature infants have the capability to quickly metabolize and eliminate BPA from the body, similar to adults.
"The BPA exposures for all of the infants in this study are short-term, limited to the time when life-saving medical treatment is necessary, and well below government-set safe intake limits for BPA, which are conservatively set. The authors acknowledge that exposures were 'below the U.S. Environmental Protection Agency reference dose (RfD) (dose below which no adverse health effects should result from a lifetime of exposure).'"Overall, the results of this study are consistent with U.S. Food and Drug Administration policy to maximize the benefits of medical devices with minimal risk."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV